DiNuzzo Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

DiNuzzo Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49K	Sell	26 -1	-4%	-$55	﹤0.01%	780
2026 Q1	$1.53K	Buy	27 +1	+4%	+$58	﹤0.01%	738
2025 Q4	$1.55K	Buy	26 +14	+117%	+$762	﹤0.01%	732
2025 Q3	$700	Hold	12	–	–	﹤0.01%	999
2025 Q2	$660	Sell	12 -12	-50%	-$707	﹤0.01%	989
2025 Q1	$1.7K	Buy	24 +11	+85%	+$740	﹤0.01%	649
2024 Q4	$855	Sell	13 -11	-46%	-$737	﹤0.01%	900
2024 Q3	$1.69K	Buy	24 +3	+14%	+$251	﹤0.01%	671
2024 Q2	$1.73K	Buy	21 +3	+17%	+$250	﹤0.01%	575
2024 Q1	$1.57K	Sell	18 -1	-5%	-$90	﹤0.01%	564
2023 Q4	$1.83K	Buy	+19	New	+$1.68K	﹤0.01%	475

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DiNuzzo Private Wealth's BMRN Position: Q2 2026 in Review

DiNuzzo Private Wealth reduced its BioMarin Pharmaceuticals (BMRN) stake by 3.7% in Q2 2026, selling an estimated $55 and leaving 26 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #780.

DiNuzzo Private Wealth first reported a position in BMRN in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.83K in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

DiNuzzo Private Wealth held 26 shares of BioMarin Pharmaceuticals worth $1.49K as of Q2 2026.
DiNuzzo Private Wealth sold 1 BioMarin Pharmaceuticals share in Q2 2026, an estimated $55.
BioMarin Pharmaceuticals made up ﹤0.01% of DiNuzzo Private Wealth's portfolio in Q2 2026, its #780 holding.
DiNuzzo Private Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
DiNuzzo Private Wealth's BioMarin Pharmaceuticals position peaked at $1.83K in Q4 2023.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on DiNuzzo Private Wealth's 13F filing for Q2 2026, filed 10 Jul 2026.